IL-2 immunotherapy fails to benefit HIV-infected individuals already taking antiretrovirals
Tuesday, February 10, 2009 - 23:07
in Health & Medicine
Providing a synthetic form of the immune system protein interleukin-2 (IL-2) to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.